Position in EXEL
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$3,643,761
+$2,574,823 QoQ
Shares Held
84,956
+250.3% QoQ
Ownership
0.034%
of shares outstanding
% of Portfolio
0.24%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
5 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in EXEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026LANDSCAPE CAPITAL MANAGEMENT, L.L.C. holds $39,756,155 across 40 Biotechnology names. EXEL ranks #3 (9.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
8,456 | $4,426,460 | |
| 2 | HALO |
Halozyme Therapeutics, Inc.
|
57,443 | $3,712,540 | |
| 3 | EXEL |
Exelixis, Inc.
This page
|
84,956 | $3,643,761 | |
| 4 | ABVX |
Abivax S.A.
|
30,353 | $3,379,805 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,935 | $3,040,338 | |
| 6 | VKTX |
Viking Therapeutics, Inc.
|
82,315 | $2,678,529 | |
| 7 | NKTR |
Nektar Therapeutics
|
36,907 | $2,655,457 | |
| 8 | AXSM |
Axsome Therapeutics, Inc.
|
14,129 | $2,388,082 |
All Filings in EXEL
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,643,761 | 84,956 | Shares | Defined | 2026-05-12 | |
| 2025-06-30 | $1,068,938 | 24,250 | Shares | Defined | 2025-08-12 | |
| 2025-03-31 | $864,924 | 23,427 | Shares | Defined | 2025-05-14 | |
| 2024-12-31 | $202,030 | 6,067 | Shares | Sole | 2025-02-12 | |
| 2024-09-30 | $720,631 | 27,770 | Shares | Sole | 2024-11-08 | |
| No filing history on record for this holder in this stock. | ||||||